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Malignant melanoma represents an important challenge to 
the clinician and scientist. Although substantial progress has 
been made in the diagnosis of early lesions, the systemic therapy 
of advanced disease urgently requires new agents. This situation 
exists despite the fact that malignant melanoma possesses 
features that should render it particularly susceptible to selec-
tive chemotherapy. First, melanocytes serve a nonessential role 
in the host, and therefore, potential agents need not discrimi-
nate between normal and malignant cells, but rather between 
melanocytic and nonmelanocytic cells. This feature obviates 
the dilemma that traditionally faces the cancer chemotherapist; 
specifically, the incorporation of tumor selectivity into the 
design of the drug. Second, melanocytes possess a unique phe-
notype (Figure), containing the enzyme tyrosinase, a poly-
phenol oxidase, which catalyzes the oxidation of tyrosine to 
levodopa to dihydroxyindole and ultimately to the biopigment 
melanin. Although there is controversy as to whether tyrosinase 
alone or peroxidase are the enzymes involved, it is clear that 
these conversions are carried on to a greater degree within 
melanocytes. Since this enzymatic activity is restricted to mel-
anocytes and is generally present in larger amounts in mela-
noma cells, a defined biochemical target is present. Third, 
melanoma cells are responsive to a specific polypeptide hor-
mone, melanocyte stimulating hormone (MSH) which causes 
an increase in pigmentation and a decrease in growth, thereby 
further enhancing the difference between melanocyte and non-
melanocyte. Fourth, conventional agents are most effective 
against rapidly dividing cells with tumor cells generally dem-
onstrating an inverse relationship between rate of growth and 
phenotypic maturation. As a correlary of these features, mela-
noma specific agents should be complementary to conventional 
agents and most effective against the slowly growing, deeply 
pigmented cells which are least susceptible to conventional 
agents therefore suggesting the possibility of combination 
chemotherapy. During the past several years, advances have 
been made toward specific approaches to the therapy of mela-
noma and we shall review some recent developments. 
BACKGROUND 
Human depigmentation signifying the destruction of melan-
ocytic cells occurs in a variety of spontaneous forms including 
vitiligo, halo nevi, and halo metastasis of melanoma. Depig-
mentation has also been reported to occur as a result of exposure 
of human skin to a variety of compounds in common use and 2 
of these compounds, hydroquinone and the monobenzylether 
of hydroquinone, have been employed extensively for the treat-
ment of pigmentary disturbances characterized by increased 
pigmentation [1]. Several studies have confirmed the ipherent 
cytotoxicity of mono- and dihydroxylated benzene derivatives 
for the pigment cell in vivo and in vitro and it has been 
suggested that melanin producing cells contain and produce 
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compounds that might be autotoxic [2-4]. It is apparent from 
the Figure that the major metabolites in the pigment pathway 
may be grouped into 1 of 3 categories and considered to be 
related to either tyrosine (monohydroxy), levodopa (dihy-
droxy), or 5,6-dihydroxyindole. Derivatives representing each 
of these categories have been examined as potential models for 
the design of compounds that will exhibit useful clinical cyto-
toxicity for melanoma cells. It should be stressed that the 
rationale for these approaches is not to interfere with melanin 
biosynthesis because melanin production is not essential to the 
general metabolic economy of the melanoma cell, but rather to 
design compounds which are converted to cytotoxic derivatives 
by the action of a unique enzymatic apparatus within the 
melanoma cell. 
TYROSINE 
The initial intermediate in the biosynthet.ic pathway for the 
formation of melanin is tyrosine. Tyrosine may be considered 
to be a momohydroxy derivative of benzene and electronically 
corresponds to a phenol. Tyrosine serves as the starting mate-
rial for the biosynthesis of melanin and is also an important 
substrate for melanoma cells in vitro. The degree of pigmenta-
tion of melanoma cells can be influenced by changing the 
concentration of tyrosine in the growth medium [5]. Raising 
the concentration of tyrosine causes an increase in cellular 
pigmentation. Furthermore, tyrosine levels may be elevated 
sufficiently to cause toxicity to pigment producing cells as 
compared to their nonpigmented counterparts [6]. Further 
discussion of the mechanism of cytotoxicity will be discussed 
under Levodopa Analogs. This technique has proved to be a 
biologically useful method of generating amelanotic clones of 
melanoma cells starting from mixed populations. A major ob-
stacle to applying this approach for the chemotherapy of mel-
anoma has been that tyrosine is one of the naturally occurring 
amino acids and is therefore used extensively in general cellular 
protein synthesis. Rapidly growing pigmented cells incorporate 
only about 5% of exogenous tyrosine into pigment with the 
remainder entering protein synthesis [7]. Since tyrosine levels 
present in mammals like those of other amino acids are under 
rigid homeostatic control, attempts to raise or lower levels of 
tyrosine in vivo have met with limited success. 
A major factor influencing the cytotoxicity of tyrosine to 
melanoma cells is the ratio of tyrosine level to specific activity 
of tyrosinase within the cell. A potential solution to the problem 
of elevation of tyrosine levels may be to elevate the level of 
tyrosinase present in the melanoma cells themselves. The avail-
ability of a hormone for enhancing pigmentation, a-MSH, sug-
gests a possible method for implementing this approach. a-
MSH has been shown to cause a marked enhancement of 
pigmentation of the B-16 melanoma in vivo and there was a 
suggestion that the tumor volun1e itself was somewhat inhibited 
[8]. In vitro experiments suggest that a-MSH is inhibitory to 
the growth of pigment-producing cells, an effect that may be 
mediated either through the elevation of intracellular cyclic 
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AMP levels or alternatively through the effects of tyrosine and 
enhanced pigmentation directly [9]. Since the phenotypic dif-
ferentiation could be further induced by the addition of phos-
phodiesterase inhibitors such as theophylline which result in a 
synergistic increase in pigmentation, it is possible that clinically 
useful cytotoxicity could be obtained. Sufficient cytotoxicity 
can be generated using this approach to reduce significantly 
both the clonogenic and tumorigenic potential of murine mel-
anoma cells reinjected into animals. Evaluation of this approach 
in humans needs detailed clinical pharmacologic control of a-
MSH administration [10]. 
Several other approaches using phenol derivatives have been 
explored. An interesting approach has recently been described 
using the synthesis and production of naturally occurring phe-
nolic precursors isolated from the common mushroom, Agari-
cus bisporus. These compounds are derivatives of L-glutamic 
acid (y-4-hydroxyanilides) and appear to function as natural 
growth regulators in the mushroom. Under the influence of 
tyrosinase present in the mushroom, ·these compounds are 
readily converted to quinone-like intermediates which are ca-
pable of inducing a cryptobiotic state in the mushroom char-
acterized by the inhibition of macromolecule biosynthesis 
[11]. Recently, it has been demonstrated that the parent phenol 
is inhibitory to the growth of murine B-16 melanoma in vivo 
and in vitro, presumably because mammalian melanoma cells 
also possess tyrosinase, and are able to convert the phenol to 
the inhibitory quinone [12]. We have prepared and examined 
the effects of a variety of monohydroxy and dihydroxy analogs 
of this quinol in an attempt to enhance the potency of these 
compounds [13]. 
LEVODOP A-DOPAMINE 
The second point of entry into the biochemical apparatus of 
the melanoma cell occurs at the level of levodopa conversion. 
lt has been shown that levodopa, unlike tyrosine, is selectively 
incorporated into melanoma cells. Although levodopa is an 
amino acid, it is not normally found in cellular proteins. 
Through the use of levodopa decarboxylase inhibitors, which 
limit the catabolism of levodopa, enhanced incorporation into 
melanoma tissues could be achieved in vivo [14]. This approach 
appeared attractive, since levodopa is intrinsically more selec-
tive than tyrosine and we proceeded to examine the effect of 
levodopa and dopamine upon the growth of melanoma cells in 
vitro. We were gratified to observe that levodopa was selectively 
toxic to pigmented cells in vitro and that through the use of its 
more water soluble analog, levodopa methyl ester, in vivo 
antitumor activity in the experimental B-16 melanoma was 
observed for the first time using a melanin precursor [15,16]. 
Interestingly, it was noted that levodopa was also capable of 
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inhibiting the growth of other tumor cells including the C1300 
neuroblastoma and murine L1210 lymphocytic leukemia cells, 
although quantitatively, the degree of inhibition observed in 
these nonmelanocytic cells was always less than that observed 
for tyrosinase positive cells [17,18). The major metabolite of 
levodopa, dopamine, which is also effectively incorporated into 
melanocytic cells, was observed to be a highly potent inhibitor 
against the B-16 melanoma in vivo and in vitro [19]. 
Recent studies have revealed several interesting features 
concerning the mechanism of action of these derivatives [18]. 
First, these compounds appear to exert a selective inhibitory 
effect on thymidine incorporation with relatively lesser effects 
upon uridine or leucine incorporation. Second, ·these drugs 
exhibited a specific effect upon the cell cycle traverse, namely, 
the production of a block at the G1S interface. Thii·d, the 
inhibition of thymidine incorporation was noted to occur very 
early, being essentially complete as soon as 5 min after exposure 
to drug. Fourth, similar kinetics of inhibition were observed for 
other nucleotides suggesting that the inhibition occurred at a 
point where each of these precursors of DNA synthesis were 
equally utilized. DNA polymerase itself was suggested to be the 
site of action. This hypothesis was tested by examining the 
effect of these analogs upon isolated mammalian DNA polym-
erase [20]. A highly effective inhibition of this enzyme was 
noted when the analog and tyrosinase enzyme were present in 
the reaction mixture together. The parent quinols themselves, 
in the absence of tyrosinase, were not inhibitory to DNA 
polymerase. Addition of either preformed quinone or tyrosinase 
which permits the generation of quinone in situ, restored inhib-
itory properties of these drugs. A second consequence of these 
experiments indicated that the quinones rather than the quinols 
were the inhibitory species. Furthermore, one of the analogs, 
3,4-dihydroxybenzylamine, which was unable to cyclize to a 
dihydroxy indole derivative, was the most potent derivative. 
This observation suggests that catechols and quinones them-
selves were capable of possessing cytotoxicity and that subse-
quent conversion to an indole derivative was not necessary for 
activity. 
These experiments suggested a model of the melanoma cells 
in vitro, with tyrosinase representing the unique phenotype of 
the melanoma cell and DNA polymerase representing its pro-
liferative thrust. Following entry of quinol into the cell, it is 
converted to quinone by tyrosinase present. The quinone in 
turn interacts with DNA polymerase which is known to be a 
sulfhydryl dependent enzyme and sensitive to oxidizing condi-
tions. The result of these interactions is inactivation of DNA 
polymerase with a consequent inhibition of cellular growth and 
ultimately cell death. The experimental model also provides a 
convenient approximation of conditions present within the mel-
anoma cell with a close juxtaposition of tyrosinase and DNA 
polymerase thereby permitting the evaluation of the effective-
ness of new derivatives. The model permits the drugs to be 
judged for their ability to be activated by tyrosinase as well as 
to subsequently inhibit DNA polymerase. Although the mech-
anisms of activation of these drugs within other tumor cells 
such as leukemia cells and neuroblastoma cells is not clear, it is 
possible that other enzymes are found in these cells such as 
myeloperoxidases. Alternatively, selectivity may be related to 
differing levels of superoxide dismutase which has recently been 
shown to be deficient in tumor cells [21]. 
Several analogs of levodopa have now been examined which 
provide insight into tpe relationship of structure and activity. 
Levodopa is somewhat unique among antitumor agents in that 
the dose limiting toxicity which appears to be neurotoxicity 
operates by a mechanism other than its antitumor effect. For 
example, one of the analogs, 6-hydroxydopa, has been shown to 
be highly potent in terms of selective toxicity for melanoma 
cells in vitro [22]. The ICso of 6-hydroxydopa was approximately 
90 times less than that observed for levodopa itself. After 
extensive in vivo evaluation of this derivative, it appears to be 
too toxic for the demonstration of in vivo antitumor activity 
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since 6-hydroxydopa has unique neurotoxic properties that 
result in the selective degeneration of adrenergic nerves. 
In an a ttempt to retain in vitro antitumor activity while 
limiting neurotoxicity several other analogs of levodopa have 
been prepared [18]. Recent results have suggested that one of 
these derivatives, 3,4-dihydroxybenzylamine, may represent 
compounds at the opposite extreme. With this derivative, we 
are able to completely limit the neuroagonist effect intrinsic in 
these drugs and separate them from their antitumor effects. 
For example, 3,4-dihydroxybenzylamine has shown equivalent 
antitumor activity in vitro yet possesses a 2-fold greater in vivo 
tolerated dose and therefore, an enhanced therapeutic response 
was observed by increased delivery of drug. 
DIHYDROXYINDOLE 
The third intermediate in the melanin pathway is 5,6-dihy-
droxyindole. It has been reported that dihydroxyindole is cy-
totoxic to melanoma cells in vitro [22]. This compound is an 
extremely reactive nucleophile and electrophile, and this reac-
tivity might limit the role of indole as antitumor agents. Fur-
thermore, when dopachrome derivatives, which are dihydroxy 
derivatives rela ted to dihydroxyindoles are examined for DNA 
polymerase inhibitory activity, they appear to be less effective 
than orthoquinones as inhibitors of this enzyme thereby sug-
gesting that their cytotoxicity is mediated by a different mech-
anism. As mentioned previously, these mechanisms may be 
related to the generation of superoxide radical. 
SUMMARY 
Significant progress has been made toward a rational ap-
proach to the chemotherapy of melanoma. Because of the 
limitations of this review, we have restricted our comments to 
those approaches that utilize the melanin synthetic apparatus. 
Although the exact details of the mechanism of action of these 
agents remain to be elucidated, the general phenomena outlined 
here might serve as a model for chemotherapy of cancer. The 
unique features are yet to be identified at the molecular level in 
most tumors, but this situation may well change as detailed 
biochemical differences of the different tumor cell types are 
uncovered and will ultimately permit the design of drugs that 
are selective against other tumors. 
In addition, important biochemical properties of catechol-
amines have been identified where intracellular effects are 
involved. These findings may have implications for other bio-
logic effects of these drugs and it is possible that the action of 
levodopa now observed in the treatment of neurological disor-
ders may be mediated to some extent by intracellular mecha-
nisms identified in the antitumor studies. Similarly, if DNA 
polymerase is the target of these drugs, additional insights into 
the mechanism of action of this important enzyme may be 
obtained, especially since the quinol-quinone interaction in the 
dopa series probe into the fundamental redox properties of a 
tumor cell. Finally, since levodopa and dopamine have had 
extensive use in humans, an opportunity exists for the rapid 
clinical evaluation of the potential role of these compounds. 
With the availability of analogs of improved activity, the rapid 
application of basic scientific advances to clinical medicine may 
be anticipated. 
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